Protocols
HCRN-GU18-343-ABATE Phase II OPEN TO ACCRUAL
A Phase 2 Study of CAbozantinib in combination with AtezolizumaB as NeoAdjuvant Treatment for Muscle-Invasive BladdEr Cancer (ABATE)